Abstract 1847P
Background
With the increasing number of oncologic patients, consultation time per patient shortens, which negatively affects the doctor – patient relationship. Participation in psychotherapeutic groups can help patients gain trust in their treatment. The aim of this study is to quantify the effects of Simonton-training on the psychological state, quality of life and compliance in oncologic patients.
Methods
This survey was carried out at the University of Debrecen in the course of a 12-occasion-long Simonton training. A total of 27 patients in the psychotherapeutic group, and 63 patients in the control group were included in this study. Patients filled out an online questionnaire three times, before the training (t0), right after the training (t1), and again 3 months later (t2). The online questionnaire contained: The Hospital Anxiety and Depression Scale (HADS), WHO Quality of Life 5-item questionnaire (WHO QOL5), Morisky Medication Adherence Scale (MMAS-8) and five questions (5Q) about the general attitude towards their treatment and the trust in their oncologist. The distribution of continuous variables was statistically analysed with the Shapiro-Wilk test, and Wilcoxon test was used for comparisons between the case and control groups due to the non-normal distribution of the majority of variables.
Results
From t0 to t1, the Simonton group’s quality of life significantly increased (p=0,016), meanwhile the control group’s QoL didn’t change significantly (p=0,575). According to HADS scale, the Simonton group’s anxiety significantly decreased from t0 to t1 (p=0,0005), and the change of the control wasn’t significant (p=0,247). Depression values also showed a significant decrease for the Simonton group from t0 to t1 (p=0,003), whereas the control’s depression values didn’t change significantly (p=0,122). After psychotherapy, the Simonton group evaluated their therapy-related attitude better with the 5Q, than at t0 (p=0,026). During this time, the control’s value didn’t change significantly (p=0,532).
Conclusions
On the basis of this study the Simonton training had a positive impact on the patients' psychological state and their quality of life increased.
Clinical trial identification
DE RKEB/IKEB 5773-2021.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05